The Eurostars project has undergone a strategic refinement to increase its clinical relevance and societal impact by shifting the proof-of-concept (POC) drug from an octreotate-based radiopharmaceutical to a PSMA-targeting therapeutic agent (²¹¹At-AstraProst) for the treatment of metastatic prostate cancer. This change leverages promising preclinical and GMP-ready data for PSMA compounds and allows the project to target a more prevalent disease with high unmet clinical need. The project continues to build on the TetraKit platform, a novel solution for automating radiolabeling with astatine-211.

Elysia-Raytest contributes its expertise in radiochemistry technology, including the development of synthesis modules, quality control systems, and HPLC purification tools. In this project, Elysia has developed the C100 synthesis module, specifically designed for labeling radiopharmaceuticals with astatine-211.

Rigshospitalet is one of only two sites in the EU that routinely produce astatine-211. Equipped with a Scanditronix MC32 cyclotron, the hospital provides the radionuclide supply and technical expertise to increase ²¹¹At production yields during the project.

To support the clinical translation of the therapeutic agent, Eurostars has approved and agreed to partially fund a First-in-Human (FIH) diagnostic validation study using ¹⁸F-PSMA, which will deliver critical imaging, dosimetry, and safety data to de-risk and accelerate the path to clinical application for ²¹¹At-AstraProst.